Tempus AI delivered 83% year-over-year revenue growth in Q4 2025, driven by Diagnostics expansion, with gross margin improvement and positive adjusted EBITDA, though it remained GAAP unprofitable.

Tempus AI delivered exceptional year-over-year revenue growth in Q3 2025, driven by strength in both Genomics and Data & Services. The company posted a net loss but achieved positive adjusted EBITDA, marking a key profitability milestone.

Tempus AI delivered Q2 2025 revenue of $314.6M, up 89.6% year-over-year, with significant growth in genomics and improved gross margin. The company narrowed its net loss compared to last year and continued to expand AI-driven healthcare tools.

Tempus AI delivered a significant 75.4% revenue growth in Q1 2025, driven by both Genomics and Data & Services segments. Despite a net loss, the company showed operating leverage and improved Adjusted EBITDA. Strategic partnerships with AstraZeneca and Pathos highlight future growth opportunities.

Tempus AI Inc saw a 35.8% year-over-year revenue growth in Q4 2024, reaching $200.7 million. The company reported a net loss of $13.0 million, significantly improving from the prior year's loss. Adjusted EBITDA also improved, and gross profit increased by 49.7%, driven by the growth in Data and Services. The company also announced its acquisition of Ambry Genetics, which is expected to strengthen its market position.